2002
DOI: 10.1182/blood-2002-09-2800
|View full text |Cite
|
Sign up to set email alerts
|

Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

3
109
0
10

Year Published

2004
2004
2015
2015

Publication Types

Select...
5
4

Relationship

0
9

Authors

Journals

citations
Cited by 193 publications
(122 citation statements)
references
References 29 publications
3
109
0
10
Order By: Relevance
“…7 In addition, retrovirus has been used widely to transduce tumor cells and immune cells for cancer therapy. [8][9][10] Retroviral vectors have also been used successfully in human trials to correct gene deficiencies in diseases including ADA-SCID, [11][12][13][14] X-linked SCID 15,16 and chronic granulomatous disease. 17 Retroviruses insert their genes in a semirandom manner into host chromosomes, 18 and it is thought that retroviruses may integrate preferentially into transcriptionally active sites.…”
Section: Introductionmentioning
confidence: 99%
“…7 In addition, retrovirus has been used widely to transduce tumor cells and immune cells for cancer therapy. [8][9][10] Retroviral vectors have also been used successfully in human trials to correct gene deficiencies in diseases including ADA-SCID, [11][12][13][14] X-linked SCID 15,16 and chronic granulomatous disease. 17 Retroviruses insert their genes in a semirandom manner into host chromosomes, 18 and it is thought that retroviruses may integrate preferentially into transcriptionally active sites.…”
Section: Introductionmentioning
confidence: 99%
“…Transduced cells were reinfused into the subjects, in whom new ADA expression could subsequently be detected for up to 12 years. 29,30 The patients experienced no ill effects and have remained in stable condition. However, the gene transfer was not efficient enough to produce clinical benefit.…”
Section: Progress Of Gene Therapy For Primary Immunodeficiencies Adenmentioning
confidence: 99%
“…PEG-ADA therapy significantly increases the numbers of T and B cells of most patients with ADA deficiency and therefore removes the selective advantage that the gene-corrected cells might have. Among the important observations arising from this trial were the documentation of the longevity of correction in transduced and differentiated T cells (one patient still carries the transduced gene in approximately 20% of her peripheral blood lymphocytes), 30 as well as the development of antibodies to FCS that were used during the ex vivo culture. 32 FCS has been omitted from subsequent trials.…”
Section: Progress Of Gene Therapy For Primary Immunodeficiencies Adenmentioning
confidence: 99%
“…From a strictly virological perspective, viral tropism refers to all cell types in which virus entry leads to the production of viral progeny, or cell types that maintain this production potential with 'dormant' viruses. As for all retroviruses, this is of particular importance in the context of HTLV, due to the stable integration of the viral genome in infected cells including T lymphocytes, whose in vivo lifespan may exceed a decade (Muul et al, 2003). Pathogenic effects are thus additional properties, that obviously depend directly on cell tropism but that, strictly speaking, do not participate in its definition.…”
Section: Cell Type-specific Pathogenesis Versus Tropismmentioning
confidence: 99%